Stock Scorer

EQL Pharma AB (EQL.ST)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 03-31. Amounts in SEK. Every figure as a table ›

Revenue Annual

0 150M 300M 450M FY24: 264.2M FY25: 373.5M FY26: 432.7M FY24 FY25 FY26

Gross Profit Annual

0 60M 120M 180M FY24: 115M FY25: 156M FY26: 162.8M FY24 FY25 FY26

Operating Income Annual

0 25M 50M 75M FY24: 32.6M FY25: 67.4M FY26: 48.7M FY24 FY25 FY26

Net Income Annual

0 15M 30M 45M FY24: 22.7M FY25: 43.1M FY26: 12.5M FY24 FY25 FY26

Cost of Revenue Annual

0 100M 200M 300M FY24: 149.1M FY25: 217.6M FY26: 269.8M FY24 FY25 FY26

Operating Cash Flow Annual

-30M -20M -10M 0 10M 20M 30M FY24: -11.4M FY25: -24.7M FY26: 28.4M FY24 FY25 FY26

Free Cash Flow Annual

-45M -30M -15M 0 15M 30M 45M FY24: -12.4M FY25: -30.8M FY26: 22.9M FY24 FY25 FY26

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 15M 30M 45M FY25: 29.9M FY26: 29.9M FY27: 29.9M FY25 FY26 FY27

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS Annual

0.00 0.50 1.00 1.50 FY24: 0.76 FY25: 1.44 FY26: 0.42 FY24 FY25 FY26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.